Workflow
赛隆药业(002898) - 2024 Q4 - 年度业绩预告
SaiLongSaiLong(SZ:002898)2025-03-14 14:10

Financial Projections - The estimated net profit for 2024 is projected to be between 4.5 million and 6.5 million yuan, representing a year-on-year decline of 31.82% to 52.80% compared to 9.53 million yuan in the previous year[2]. - The estimated net profit after deducting non-recurring gains and losses is projected to be between 4.2 million and 6.2 million yuan, compared to a loss of 2.44 million yuan in the previous year[2]. - The estimated total operating revenue for 2024 is expected to be between 270 million and 320 million yuan, with a net profit margin indicating potential financial challenges[6]. - The basic earnings per share are estimated to be between 0.0256 yuan and 0.0369 yuan, down from 0.0542 yuan in the previous year[2]. Non-Recurring Gains and Losses - Non-recurring gains and losses decreased by approximately 11.65 million yuan, with the current period's amount at about 300,000 yuan compared to 11.97 million yuan in the previous year[4]. Expense Management - The company has successfully controlled various expenses, leading to a decrease in sales, research and development, and management expenses during the reporting period[5]. Audit and Estimates - The company has communicated with the accounting firm regarding the preliminary estimates, and there are no significant discrepancies noted[3]. - The company warns that the preliminary estimates are subject to change pending audit confirmation and third-party asset evaluations, which may impact the final financial data[6]. Risk Warnings - If the audited profit total, net profit, and net profit after deducting non-recurring gains and losses are negative, and the adjusted operating revenue is below 300 million yuan, the company's stock may face delisting risk warnings[6]. - The company emphasizes the importance of investors monitoring official disclosures and exercising caution in their investment decisions[7].